期刊
JOURNAL OF MEDICAL TOXICOLOGY
卷 16, 期 3, 页码 284-294出版社
SPRINGER
DOI: 10.1007/s13181-020-00777-5
关键词
COVID-19; SARS-CoV-2; Toxicity; Pandemic; Therapeutic
类别
资金
- Loan Repayment Program (National Institute on Drug Abuse, National Institutes of Health)
- Loan Repayment Program (National Center for Advancing Translational Sciences, National Institutes of Health)
SARS-CoV-2 is a novel coronavirus that emerged in 2019 and is causing the COVID-19 pandemic. There is no current standard of care. Clinicians need to be mindful of the toxicity of a wide variety of possibly unfamiliar substances being tested or repurposed to treat COVID-19. The United States Food and Drug Administration (FDA) has provided emergency authorization for the use of chloroquine and hydroxychloroquine. These two medications may precipitate ventricular dysrhythmias, necessitating cardiac and electrolyte monitoring, and in severe cases, treatment with epinephrine and high-doses of diazepam. Recombinant protein therapeutics may cause serum sickness or immune complex deposition. Nucleic acid vaccines may introduce mutations into the human genome. ACE inhibitors and ibuprofen have been suggested to exacerbate the pathogenesis of COVID-19. Here, we review the use, mechanism of action, and toxicity of proposed COVID-19 therapeutics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据